Head And Neck Cancer
The approval was based on evidence from animal study data, human pharmacokinetic and pharmacodynamics data, and clinical immunogenicity data which demonstrated Mvasi is a biosimilar to Avastin.
Overall, 1.5% of all patients and 27.8% of those who initially tested positive had persistently positive results on the repeated sample four weeks later.
Data from 2,627 Americans, aged 18 to 33, were analyzed to assess the effect of self-reported receipt of at least one dose of an HPV vaccine on oral HPV infection.
Orphan designation has also been granted to copanlisib for the treatment of splenic, nodal, and extranoldal subtypes of marginal zone lymphoma.
The researchers found that the median progression-free survival was 6.7 and 4.0 months for patients treated with TTFields/TMZ and TMZ alone, respectively.
The FDA has approved Opdivo (nivolumab; Bristol-Myers Squibb) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or after platinum-based chemotherapy or for those who have disease progression within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy.
For patients with laryngeal squamous cell carcinoma (SCC), factors predictive of recurrence include neck metastasis at presentation and nonsurgical treatment, according to a study published online November 30 in Head & Neck.
An updated index incorporating gene and molecular alterations can predict survival in non-small-cell lung cancer (NSCLC) with brain metastases.
A radiomic-based approach can be used to generate a prediction model for stratifying treatment outcome among patients with recurrent glioblastoma prior to bevacizumab treatment, according to a study published online in Clinical Cancer Research.
Nivolumab is associated with longer overall survival than standard single-agent therapy in patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, according to a study published online in the New England Journal of Medicine.